Laffer Tengler Investments Gilead Sciences, Inc. Transaction History

Laffer Tengler Investments

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$73.94 - $80.67 $643,278 - $701,829	-8,700 Reduced 99.49%	45 $3.37 Million
Q2 2023 Aug 14, 2023	BUY	$76.01 - $86.7 $99,801 - $113,837	1,313 Added 17.67%	8,745 $674 Million
Q1 2023 May 09, 2023	SELL	$77.31 - $88.08 $89,679 - $102,172	-1,160 Reduced 13.5%	7,432 $617 Million
Q4 2022 Feb 10, 2023	BUY	$62.32 - $89.47 $114,357 - $164,177	1,835 Added 27.16%	8,592 $738 Million
Q4 2021 Feb 11, 2022	BUY	$64.88 - $73.64 $39,836 - $45,214	614 Added 10.0%	6,757 $491 Million
Q3 2021 Nov 16, 2021	BUY	$67.69 - $73.03 $62,342 - $67,260	921 Added 17.64%	6,143 $429 Million
Q2 2021 Aug 16, 2021	BUY	$63.47 - $69.35 $233,823 - $255,485	3,684 Added 239.53%	5,222 $360 Million
Q1 2021 May 17, 2021	BUY	$60.0 - $68.46 $18,420 - $21,017	307 Added 24.94%	1,538 $99.4 Million
Q4 2020 Feb 19, 2021	BUY	$56.65 - $64.55 $69,736 - $79,461	1,231 New	1,231 $71.7 Million

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Laffer Tengler Investments, based on Form 13F filings with the SEC.

Stay updated on Laffer Tengler Investments with notifications on news.